What is GHK-Cu? Copper binding, gene data and the limits of the human evidence
What is GHK-Cu? A copper(II)-binding tripeptide in human plasma, with cell, animal and gene data but human evidence limited to small topical cosmetic studies.
What is GHK-Cu? It is the copper(II) complex of GHK, a three-amino-acid peptide (glycyl-histidyl-lysine) found naturally in human plasma. Most of what is known comes from cell culture, animal wound models and small cosmetic studies. Controlled human evidence outside topical skin care is essentially absent.
This post walks through the copper chemistry, the cell and gene-expression data, and where the human data stop. It also flags a sourcing issue: most of the literature summaries come from one research group.
What is GHK-Cu, chemically?
GHK was first described by Loren Pickart in 1973. It was isolated as an activity in human albumin that made old human liver tissue synthesize proteins like younger tissue. Later work identified the activity as a tripeptide that binds copper.
In the GHK-Cu complex, the Cu(II) ion is held by three nitrogens:
- the imidazole nitrogen of histidine,
- the alpha-amino nitrogen of glycine,
- a deprotonated amide nitrogen from the peptide backbone.
A 2015 review in BioMed Research International gives a binding constant for GHK of log10 = 16.44, against 16.2 for albumin. That puts GHK in the same range as the main copper carrier in blood. The same review states that bound copper loses its redox activity, which matters for oxidative-stress claims.
Because the copper is part of the molecule, copper content is a real quality variable. Our guide to copper content in GHK-Cu covers how it is measured. For how the free peptide differs from the complex, see GHK vs GHK-Cu.
Plasma levels and the aging hypothesis
Reviews report plasma GHK at about 200 ng/mL (roughly 10-7 M) at age 20, falling to about 80 ng/mL by age 60. The reviews state these figures without citing the underlying measurement study inline.
That decline is the basis for describing GHK as an "aging" peptide. A falling level does not show that the peptide causes any age-related change. It is a correlation, and the original data are not presented in the reviews.
Cell and animal findings
Most mechanistic claims come from cultured cells. The main reported findings include:
- Matrix proteins. At 1–10 nanomolar, GHK-Cu stimulated both synthesis and breakdown of collagen and glycosaminoglycans. It also increased decorin and modulated metalloproteinases and their inhibitors TIMP-1 and TIMP-2.
- Irradiated fibroblasts. Human fibroblasts exposed to 5,000 rad grew faster with GHK at 10-9 M than untreated irradiated cells.
- Lung fibroblasts. In fibroblasts from people with COPD, GHK restored collagen gel contraction to the level of cells from ex-smokers.
- Oxidation in a test tube. GHK fully blocked copper-driven LDL oxidation, while the enzyme SOD1 gave about 20% protection. GHK-Cu reduced iron release from ferritin by 87%.
Animal studies are mostly wound models. The reviews describe faster wound healing and more blood-vessel formation in rabbits, and wound effects in rats, mice, pigs and dogs. They report no group sizes or effect sizes for these studies, so the strength of each result cannot be judged from the reviews alone.
For a framework on weighing this kind of data, see how to read preclinical research.
The gene-expression data
The most-cited GHK claim is that it changes the expression of about 4,000 human genes. This comes from the Broad Institute Connectivity Map, a public database of drug-induced expression profiles.
The 2015 Cosmetics review describes the method. It used three GHK profiles, two from PC3 prostate cancer cells and one from MCF7 breast cancer cells. A gene counted if its expression changed by 50% or more. By that cutoff, 31.2% of the genes measured were affected.
| Data point | Reported value | Model |
|---|---|---|
| Genes changed ≥50% | 31.2% of genes measured | PC3 and MCF7 cancer cell lines |
| Metastatic colon cancer signature | Expression suppressed in 70% of 54 overexpressed genes, at 1 µM | Connectivity Map screen of 1,309 compounds |
| COPD signature | Reversed a 127-gene pattern linked to emphysema severity | Lung tissue signature, then lung fibroblasts |
| Neuron-related genes | 408 up, 230 down | Gene Ontology set within the same profiles |
These numbers need context. The profiles come from cancer cell lines, not skin or healthy tissue. A change in RNA does not show a change in protein or function. The 2018 authors say of the neuron data that "we don't know exactly what this means."
The published tables also have internal inconsistencies. In the 2018 paper, the stated up/down split does not match the paper's own table. One table cell also differs from the 2015 version. Readers should treat the exact counts as approximate.
What the human data show
Human data on GHK-Cu are limited to topical cosmetic studies in women. The reviews describe several placebo- or comparator-controlled studies:
- A thigh cream study using skin biopsies. Collagen production increased in 70% of women using GHK-Cu, against 50% for vitamin C cream and 40% for retinoic acid.
- A 12-week facial cream study in 71 women with photoaging, and a 12-week eye cream study in 41 women.
- An 8-week randomized, double-blind study of a nano-lipid carrier formulation. It reported a 31.6% reduction in wrinkle volume compared with a Matrixyl 3000 product.
The reviews give few sample sizes, p-values or effect sizes for most of these. The reviews describe no human trials of GHK-Cu for any medical condition, and no systemic human studies.
The BioMed Research International review also notes that GHK-Cu is highly hydrophilic and prone to cleavage by proteolytic enzymes and oxidative stress. Both points bear on how stable the peptide is in a formulation. Our peptide storage and stability guide covers the general principles.
A note on sources
All three reviews used here come from Pickart and colleagues. They work at Skin Biology, an R&D company in Bellevue, Washington. Pickart discovered the peptide, and the group has worked on it for decades. That expertise is real, but the reviews are narrative, not systematic, and largely summarize the group's own reading of the field.
Independent replication of the gene-expression claims, and larger peer-reviewed human studies, would be needed to firm up the picture. Until then, GHK-Cu is best described as a well-characterized copper complex with substantial cell and animal data and thin human evidence. More on the compound is on the GHK-Cu compound page and in the cosmetic peptides category.
Sources
- BioMed Research International: GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration (2015)
- International Journal of Molecular Sciences: Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (2018)
- Cosmetics (MDPI): GHK-Cu may Prevent Oxidative Stress in Skin by Regulating Copper and Modifying Expression of Numerous Antioxidant Genes (2015)
Educational content only, not medical advice. Compounds discussed as research materials are for laboratory research use only and are not for human or veterinary use.
More from the blog
- Health Canada finds bacteria in seized peptide vials: the November 2026 advisories
- What is a peptide bond? Resonance, cis/trans isomers and how it forms and breaks
- Cagrilintide: what the amylin analog's trials show and where FDA review stands
- AMA urges HHS to rescind its peptide compounding policy as the comment period closes